Incyte Had a Bad Week. Investors Are Used to It.
Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...
StockStory.org on MSN3d
Why Incyte (INCY) Stock Is Nosediving
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company ...
Incyte Corp. stock underperforms Monday when compared to competitors
Shares of Incyte Corp. INCY slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the ...
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
Key Takeaways Incyte shares sank Monday after the drugmaker released the latest data from a clinical trial.The drug, ...
Incyte price target lowered to $72 from $74 at Truist
Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...
Fierce Biotech3d
Incyte posts phase 3 skin condition wins but details disappoint, sinking stock
Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Omeros Corporation OMER shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday. Neogen Corporation NEOG ...
Incyte's skin disease drug fails to impress in late-stage studies; shares drop
Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
Incyte (NASDAQ:INCY) Rating Lowered to “Market Perform” at William Blair
Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.
Incyte (INCY) Receives a Hold from Truist Financial
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...